糖皮质激素对风湿免疫病患者骨密度的影响分析

Effect of glucocorticoids on bone mineral density in patients with rheumatic immune disease

目的分析糖皮质激素对风湿免疫病患者骨密度的影响。方法选取2018年4月至2019年8月本院收治的86例风湿免疫病患者作为研究对象,按照随机对照原则分为对照组和观察组,每组43例。对照组采用常规治疗,观察组在对照组基础上采用糖皮质激素治疗。比较两组骨密度及骨代谢相关指标。结果治疗后,观察组总骨密度、Ward区骨密度低于对照组(P<0.05);两组股骨颈骨密度、L1~4前后位骨密度比较差异无统计学意义。观察组血清骨特异性碱性磷酸酶(BAP)、人骨Ⅰ型胶原羧基端前肽(PICP)均低于对照组(P<0.05)。结论采用糖皮质激素治疗风湿免疫病,可有效抑制患者骨形成标志物的产生,降低骨密度,严重影响患者骨吸收及生成情况,提高骨质疏松病症的发病率。

Objective To analyze the effect of glucocorticoids on bone mineral density in patients with rheumatic immune disease.Methods 86 patients with rheumatic immune disease admitted to our hospital from April 2018 to August 2019 were selected as the research subjects,they were divided into control group and observation group according to the principle of randomized control,with 43 cases in each group.The control group was treated with conventional treatment,and the observation group was treated with glucocorticoids on the basis of the control group.The bone mineral density and related indexes were compared between the two groups.Results The total bone mineral density and bone mineral density in the Ward area of the observation group were lower than those in the control group after treatment(P<0.05);there was no significant difference between the two groups in femoral neck bone mineral density,L1-4 anteroposterior bone mineral density.Bone specific alkaline phosphatase(BAP)and human bone type I collagen carboxyterminal propeptide(PICP)in the observation group were lower than those in the control group(P<0.05).Conclusion The use of glucocorticoids to treat rheumatic immune diseases can effectively reduce the production of bone formation markers in patients,reduce bone mineral density,seriously affect patients’bone resorption and production,and increase the incidence of osteoporosis.